| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | Gynaecological
> Gynaecological: other | Regulatory partnership
> Working with regulatory bodies | 100,000 | National | Sometimes | 115028466428 |
| We periodically prepare statements for submission as supporting documentation to drug reimbursement applications. | Not Specified
> Not specified | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 10,000 | National | Sometimes | 114998339214 |
| We periodically prepare submissions to accompany medicine reimbursement applications. | Not Specified
> Not specified | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 10,000 | National | Sometimes | 114998339214 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | Bone
> Osteoarthritis | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 10,000 | National | Regularly | 114998343058 |
| Patient organisation submissions to the authorities responsible for reimbursement decisions. | Cancer
> Cancer: breast | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 10,000 | National | Sometimes | 115043746918 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | Bone
> Osteoporosis | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100,000 | National | Regularly | 114998337721 |
| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | Gynaecological
> Gynaecological: other | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100,000 | National | Sometimes | 115028466428 |
| We submit statements to regulatory channels from a patient perspective. | Cancer
> Cancer: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | Do not know | National | Regularly | 115040330840 |
| Occasional position statements and opinions, often issued jointly with another organisation or under the auspices of an umbrella body. | Rheumatic
> Lupus | Regulatory partnership
> With other healthcare advocates | 5,000 | National | Rarely | 115002845827 |
| Where there is a need to advocate or submit a formal statement, for example, we do so. | General health
> Sexual health: other | Impacting policy and legislation
> Influence healthcare policy and legislation | 10,000 | National | Rarely | 115000148067 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | Bone
> Osteoarthritis | Impacting policy and legislation
> Participate in public hearings and consultations | 10,000 | National | Regularly | 114998343058 |
| We submit consultation responses. | Bone
> Osteoarthritis | Impacting policy and legislation
> Participate in public hearings and consultations | 10,000 | National | Regularly | 114998343058 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | Endocrine
> Diabetes (both types 1 and 2) | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 1,000 | Regional | Sometimes | 115006989892 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | Disability
> Disability: most types | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 1,000 | National | Regularly | 115007749998 |
| The price of obesity medicines. | Patient advocacy
> Health activist | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 1,000 | National | Sometimes | 115060416441 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | Skin
> Psoriasis | Pricing and affordability advocacy
> Address cost barriers for low-income and vulnerable people | 10,000 | National | Regularly | 115000293575 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | Disability
> Disability: most types | Pricing and affordability advocacy
> Address cost barriers for low-income and vulnerable people | 1,000 | National | Regularly | 115007749998 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | Endocrine
> Diabetes (both types 1 and 2) | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | Neuromuscular
> Muscular dystrophy | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 5,000 | National | Regularly | 115007479426 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | Disability
> Disability: most types | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 1,000 | National | Regularly | 115007749998 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | Skin
> Psoriasis | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 10,000 | National | Regularly | 115000293575 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | Endocrine
> Diabetes (both types 1 and 2) | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | Neuromuscular
> Muscular dystrophy | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 5,000 | National | Regularly | 115007479426 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | Bone
> Osteoporosis | Evidence-based patient input
> Use patient insights to inform decisions | 100,000 | National | Regularly | 114998337721 |
| We submit statements to regulatory channels from a patient perspective. | Cancer
> Cancer: most types | Evidence-based patient input
> Use patient insights to inform decisions | Do not know | National | Regularly | 115040330840 |
| ... We are represented on Fimea's [Lääkealan turvallisuus- ja kehittämiskeskus – Finnish Medicines Agency] patient advisory board. | Not Specified
> Not specified | Institutional governance
> Ensure representation within governmental advisory bodies | 10,000 | National | Sometimes | 114998339214 |
interactions
actions & advocacy
8 mentions
